Document is current

Article History

Received: 14 February 2023

Revised: 23 August 2023

Accepted: 30 August 2023

First Online: 11 September 2023

Competing interests

: AB declares consulting fees for ROCHE SAS. SD reports, outside the submitted work, grants and non-financial support from Pfizer, grants from Novartis, grants and non-financial support from AstraZeneca, grants and non-financial support from Roche Genentech, grants from Lilly, grants from Puma, grants from Myriad, grants from Orion, grants from Amgen, grants from Sanofi, grants from Genomic Health, grants from GE, grants from Servier, grants from MSD, grants from BMS, grants from Pierre Fabre, grants from Seagen, grants from Exact Sciences, grants from Rappta, grants from Besins, grants from European Commission grants, grants from French government grants, grants from Fondation ARC grants, grants from Taiho, grants from Elsan, SM. reports, outside the scope of the submitted work, receiving fees for statistical advice to IDDI, Amaris, and Roche, and for data and safety monitoring membership of clinical trials: IQVIA, Sensorion, Biophytis, Servier, Yuhan. BP reports, outside the scope of the submitted work, receiving personal fees from Novartis, AstraZeneca, MSD Oncology and Pfizer; receiving research funding from Daiichi, Puma Biotechnology, Novartis, Merus, Pfizer, and AstraZeneca; and serving as consultant/advisor for Puma Biotechnology, Novartis, Myriad Genetics and Pierre Fabre. IVLI reports, outside the scope of the submitted work, receiving speaker honoraria from Amgen, AstraZeneca, Pfizer/Edimark, Novartis, Sandoz; writing engagement from Pfizer/Edimark, Research funding from Resilience Care. The other co-authors declare no conflict of interest.

: The protocol of TAM01 study was approved by the Caen Committee for the Protection of Persons in Biomedical Research. The need for informed consent was waived due to nature of this study, i.e., a reanalysis of a previous published clinical trial.